We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept
PRODUCTS / PRODUCT PORTFOLIO
OTHER THERAPEUTIC AREAS

PRODUCT PORTFOLIO

Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, pain and respiratory diseases.
Product Indication Dosage form Strength
Aripiprazole Schizophrenia, bipolar disorder Tablets 5, 10, 15, 20 and 30 mg
Azithromycin Macrolide antibacterial Film-coated tablets 500 mg
Azithromycin Macrolide antibacterial Powder for oral suspension 200 mg/5 ml
Bimatoprost Intraocular pressure Eye drops, solution 0.3 mg/ml (0.4 ml unit dose)
Calcium Dobesilate * Non proliferative diabetic retinopathy Hard capsules 500 mg
Carmellose - Artificial tears Dry eye Eye drops, solution 2 mg (unit dose)
Ciprofloxacin otic Otitis Ear drops, solution (unit dose) 1 mg
Clonazepam Epilepsy Oral drops, solution 2.5 mg/ml
Clopidogrel Atherothrombosis Film-coated tablets 75 mg
Desloratadine Allergy Film-coated tablets 5 mg
Dexketoprofen Analgesic Film-coated tablets 12.5 and 25 mg
Duloxetine * Major depressive disorders, neuropathic pain, anxiety Gastro resistant hard capsules 30 and 60 mg
Enalapril Hypertension Tablets 5 and 20 mg
Enalapril + HCTZ Hypertension Tablets 20/12.5 mg
Eslicarbazepine acetate Epilepsy Film-coated tablets 800 mg
Ethosuximide Epilepsy, absence seizures Soft capsules 250 mg
Ethosuximide Epilepsy, absence seizures Oral solution 50 mg/ml
Fluconazol Antifungal Hard capsules 50, 100, 150 and 200 mg
Fluconazol Antifungal Powder for oral suspension 200 mg/5ml and 50 mg/5ml
Hypromellose - Artificial tears Dry eye Eye drops, solution 0.5 ml (unit dose)
FDF PRODUCT PORTFOLIO

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.


© Neuraxpharm / LESVI. All rights reserved.